FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W143735323> ?p ?o ?g. }

• W143735323 endingPage "14" @default.
• W143735323 startingPage "1" @default.
• W143735323 abstract "The introduction of newer and more potent agents has diverted attention away from the importance of nucleoside analogue reverse transcriptase inhibitors (NRTIs) in modern antiretroviral drug regimens. As a class, these proviral chain terminators lack the virological potency of either non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI) drugs, due largely to their competitive mode of inhibition and requirement for metabolic activation. However, neither NNRTIs nor PIs alone can maintain the complete suppression of HIV replication required for extended therapy, and both suffer from serious class cross-resistance on therapeutic failure. Thus, the NRTIs will remain essential components of highly active antiretroviral therapy (HAART) for the foreseeable future, both for their contribution to a regimen's virological potency and the subsequent preservation of the more potent drug classes used with them. However, it has become apparent in recent years that the current NRTIs exhibit duration-dependent adverse events as a class, which may limit the length of time for which they can be safely used. An independent contribution to peripheral fat wasting in lipodystrophy syndrome has been established for the use of NRTI drugs. Of greater clinical concern is their established association with potentially fatal lactic acidaemia and hepatic steatosis. Both these class events, as well as several individual drug events, such as peripheral neuropathy, can be linked to progressive mitochondrial destruction with a greater or lesser degree of confidence. Mitochondrial toxicity, due in large part to the high affinity of several NRTI agents for uptake by mitochondrial DNA polymerase γ, has been demonstrated both in vitro and in vivo. New chain-terminating agents are urgently needed that address issues of improved virological potency, greater efficacy in NRTI-experienced individuals, and greater long-term safety. The nucleotide class of reverse transcriptase inhibitor (NtRTI), currently under clinical development, addresses improved potency by abbreviating the intracellular activation pathway to allow a more rapid and complete conversion to the active agent. These nucleoside monophosphate analogues are taken as masked prodrugs bearing labile lipophilic groups to facilitate penetration of target cell membranes. Subsequent unmasking by endogenous chemolytic enzymes releases a partially activated nucleoside analogue metabolite. The NtRTI furthest along the developmental process is tenofovir disoproxil fumarate (TDF), an orally available acyclic adenine phosphonate analogue, currently in Phase III clinical trials. This agent has shown high potency and an unusually durable response in trials of single-agent therapy intensification in highly treatment-experienced individuals, and its active metabolite, tenofovir diphosphate, exhibits a long intracellular half-life in both resting and activated peripheral blood mononuclear cells that permits once daily dosing. Tenofovir diphosphate also exhibits a very low affinity for DNA polymerase γ in vitro, suggesting a low degree of in vivo mitochondrial toxicity may be observed on long-term follow-up, although clinical data to support this inference are not yet available. The introduction of TDF and other NtRTIs as ‘second-generation’ nucleoside analogues carefully evaluated for potential long-term toxicity, can be expected to significantly improve the therapeutic options for both those currently on HAART and those yet to begin." @default.
• W143735323 created "2016-06-24" @default.
• W143735323 creator A5086825885 @default.
• W143735323 date "2000-04-01" @default.
• W143735323 modified "2023-09-27" @default.
• W143735323 title "An Introduction to Nucleoside and Nucleotide Analogues" @default.
• W143735323 cites W124544113 @default.
• W143735323 cites W1482773835 @default.
• W143735323 cites W1507543762 @default.
• W143735323 cites W1529552889 @default.
• W143735323 cites W1548955637 @default.
• W143735323 cites W1552261986 @default.
• W143735323 cites W1557880692 @default.
• W143735323 cites W1560787586 @default.
• W143735323 cites W1582508691 @default.
• W143735323 cites W1665723380 @default.
• W143735323 cites W1943653788 @default.
• W143735323 cites W1955016433 @default.
• W143735323 cites W1966777431 @default.
• W143735323 cites W1967830103 @default.
• W143735323 cites W1970227309 @default.
• W143735323 cites W1972744319 @default.
• W143735323 cites W1977521763 @default.
• W143735323 cites W1978724449 @default.
• W143735323 cites W1978902758 @default.
• W143735323 cites W1979161571 @default.
• W143735323 cites W1979292200 @default.
• W143735323 cites W1984270093 @default.
• W143735323 cites W1985309622 @default.
• W143735323 cites W1993086185 @default.
• W143735323 cites W1998660799 @default.
• W143735323 cites W2000488513 @default.
• W143735323 cites W2006917652 @default.
• W143735323 cites W2010844841 @default.
• W143735323 cites W2017257729 @default.
• W143735323 cites W2019265347 @default.
• W143735323 cites W2021037491 @default.
• W143735323 cites W2022314336 @default.
• W143735323 cites W2022671360 @default.
• W143735323 cites W2024720867 @default.
• W143735323 cites W2024830974 @default.
• W143735323 cites W2028632564 @default.
• W143735323 cites W2030802762 @default.
• W143735323 cites W2031274178 @default.
• W143735323 cites W2033978085 @default.
• W143735323 cites W2036140173 @default.
• W143735323 cites W2038161589 @default.
• W143735323 cites W2038188667 @default.
• W143735323 cites W2039402593 @default.
• W143735323 cites W2041841997 @default.
• W143735323 cites W2044877337 @default.
• W143735323 cites W2046348452 @default.
• W143735323 cites W2048303439 @default.
• W143735323 cites W2049415878 @default.
• W143735323 cites W2050639356 @default.
• W143735323 cites W2055198727 @default.
• W143735323 cites W2065349954 @default.
• W143735323 cites W2070466987 @default.
• W143735323 cites W2070933534 @default.
• W143735323 cites W2076562284 @default.
• W143735323 cites W2077014185 @default.
• W143735323 cites W2077488136 @default.
• W143735323 cites W2083969161 @default.
• W143735323 cites W2084332399 @default.
• W143735323 cites W2091278864 @default.
• W143735323 cites W2099169775 @default.
• W143735323 cites W2102293583 @default.
• W143735323 cites W2113644342 @default.
• W143735323 cites W2126392945 @default.
• W143735323 cites W2141163306 @default.
• W143735323 cites W2143773220 @default.
• W143735323 cites W2152834564 @default.
• W143735323 cites W2159479663 @default.
• W143735323 cites W2160714949 @default.
• W143735323 cites W2217761141 @default.
• W143735323 cites W2311357247 @default.
• W143735323 cites W2318289184 @default.
• W143735323 cites W2330914362 @default.
• W143735323 cites W2332258345 @default.
• W143735323 cites W4240002281 @default.
• W143735323 doi "https://doi.org/10.1177/135965350100603s01" @default.
• W143735323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11678469" @default.
• W143735323 hasPublicationYear "2000" @default.
• W143735323 type Work @default.
• W143735323 sameAs 143735323 @default.
• W143735323 citedByCount "56" @default.
• W143735323 countsByYear W1437353232012 @default.
• W143735323 countsByYear W1437353232014 @default.
• W143735323 countsByYear W1437353232015 @default.
• W143735323 countsByYear W1437353232016 @default.
• W143735323 countsByYear W1437353232017 @default.
• W143735323 countsByYear W1437353232018 @default.
• W143735323 countsByYear W1437353232019 @default.
• W143735323 countsByYear W1437353232022 @default.
• W143735323 countsByYear W1437353232023 @default.
• W143735323 crossrefType "journal-article" @default.
• W143735323 hasAuthorship W143735323A5086825885 @default.
• W143735323 hasBestOaLocation W1437353231 @default.

• next